Indirectly, serum samples from tofacitinib-treated RA patients could reduce the levels of CD147, MMP-9, VEGF, and TIMP-1 secreted from HT1080 fibroblasts and enhance the levels of endostatin (Figure 8). Here, VEGFA is linked to rheumatoid arthritis.